Key Takeaways Novo Nordisk cut its 2025 sales growth outlook to 8-14%, down from its previous 13-21% forecast.The company cited slower Wegovy and Ozempic momentum amid U.S. market challenges and competition.NVO's preliminary Q2 EPS of $0.91 missed estimates; sales rose 18% and profit jumped 40% at CER.Shares of Novo Nordisk (NVO) plunged 21.8% on Tuesday after the company sharply lowered its 2025 outlook for both sales and operating profit growth, which will ultimately impact its earnings per share. The dru ...